Journal
TUBERCULOSIS
Volume 95, Issue 6, Pages 713-721Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.tube.2015.07.001
Keywords
Tuberculosis; T cell antigen; Vaccine; CD4
Categories
Funding
- National Institutes of Health [HHSN272200900044C, HHSN266200700022C/NO1-AI-70022, R37AI052731]
- IOC/FIOCRUZ [CNPq research fellowship] [PQ-2-Brazil]
- Italian Ministry of Health [Ricerca Corrente]
- Bill and Melinda Gates Foundation [OPP1066265]
- HIV Vaccine Trials Network [RAMP scholarship]
- Russian Science Foundation [15-15-00136]
- Russian Science Foundation [15-15-00136] Funding Source: Russian Science Foundation
- Bill and Melinda Gates Foundation [OPP1066265] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
We compared T cell recognition of 59 prevalently recognized Mycobacterium tuberculosis (MTB) antigens in individuals latently infected with MTB (LTBI), and uninfected individuals with previous BCG vaccination, from nine locations and populations with different HLA distribution, MTB exposure rates, and standards of TB care. This comparison revealed similar response magnitudes in diverse LTBI and BCG-vaccinated cohorts and significant correlation between responses in LTBIs from the USA and other locations. Many antigens were uniformly recognized, suggesting suitability for inclusion in vaccines targeting diverse populations. Several antigens were similarly immunodominant in LTBI and BCG cohorts, suggesting applicability for vaccines aimed at boosting BCG responses. The panel of MTB antigens will be valuable for characterizing MTB-specific CD4 T cell responses irrespective of ethnicity, infecting MTB strains and BCG vaccination status. Our results illustrate how a comparative analysis can provide insight into the relative immunogenicity of existing and novel vaccine candidates in LTBIs. (C) 2015 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available